Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed No phase listed Observational

A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.

ClinicalTrials.gov ID: NCT06467370

Public ClinicalTrials.gov record NCT06467370. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 12, 2026, 7:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

CONFIDENCE: A PROSPECTIVE OBSERVATIONAL STUDY WITH ACUTE TREATMENT OF RIMEGEPANT ODT ON CONSISTENCY, SATISFACTION AND TOLERABILITY OF TREATMENT IN THE REAL WORLD

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study aims at characterizing the effectiveness of rimegepant as an acute migraine treatment in a real world setting on two aspects: * Consistency of response to rimegepant across multiple attacks * Effectiveness of rimegepant in users taking concomitant migraine preventive medications, namely monoclonal antibodies targeting CGRP and onabotulinumtoxinA

Study identification

NCT ID
NCT06467370
Recruitment status
Completed
Study type
Observational
Phase
Not listed
Lead sponsor
Pfizer
Industry
Enrollment
467 participants

Conditions and interventions

Conditions

Interventions

Not listed

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 1, 2024
Primary completion
Mar 10, 2025
Completion
Mar 10, 2025
Last update posted
Jun 29, 2026

2024 – 2025

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Pfizer New York New York 10001

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06467370, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 29, 2026 · Synced Sep 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06467370 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →